… An improved understanding of molecular resistance is essential to optimize personalized
treatment in IBD. First studies have indicated mechanisms that drive primary resistance to …

… -treated and -untreated patients receive the same dosage of TNF-α inhibitor, a reduced ‘load‘
of TNF-α in those treated with methotrexate is likely to consume less anti-TNF-α antibody, …

… about the use of anti-tumor necrosis factor alpha (TNF-α) drugs in patients with PMR, and …
Results and Conclusions: only two anti TNF-α drugs have been prescribed to PMR patients: …

… Winding Road of TNFα in Cancer Therapy The potent pro-inflammatory cytokine tumor
necrosis factor α (TNFα) has been connected to cancer progression and treatment ever since its …

… We were not able to show decrease of TNF in patients receiving anti-TNF treatment or
reduction of IL-12 or IL-17 in patients receiving ustekinumab or secukinumab, respectively. …

… Up to 40% of patients treated with tumor necrosis factor alpha inhibitors (TNFi) do not respond
to … adjustment or switch to different drugs, enabling a personalized medicine approach. …

… on anti-TNF therapy even if they fail to achieve the treatment target, … TNF—called anti-TNF
cycling—before changing MOA. This significantly delays patients from reaching their treatment …

… The demonstration of overexpression of TNF and TNF receptors in the synovium of … treatment
of RA implies that synovial expression level of TNF may be correlated with TNFi treatment …

… The other two TNF-α antagonists are approved for both UC … TNF-α antagonists are used for
induction and maintenance … Despite the great efficacy of TNF-α antagonists in the treatment of …

… Our study contributes with new knowledge in the scientific field of personalized therapy in
UC [15, 16]. We know that treatment to remission improves long-term clinical outcome [39, 40]. …